DIA407.42+1.08 0.27%
SPX5,604.14+35.08 0.63%
IXIC17,710.74+264.40 1.52%

Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?

Benzinga·04/27/2025 15:46:27
Listen to the news

These eight mid-cap stocks were the best performers in the last week. Are they in your portfolio?

  1. Ascentage Pharma Group Internat (NASDAQ:AAPG) stock jumped 38.35%. The company plans to present data from two clinical studies at the 2025 ASCO Annual Meeting, including an oral presentation for its key assets Lisaftoclax and Alrizomadlin.
  2. Ardagh Metal Packaging (NYSE:AMBP) shares escalated 38.66% after the company reported a year-over-year increase in first-quarter adjusted EPS results and better-than-expected revenue results. Additionally, the company raised its FY25 adjusted EBITDA guidance.
  3. Bitdeer Technologies Group (NASDAQ:BTDR) stock gained 38.19% last week. Shares of crypto-related companies have gained amid a rise in the price of Bitcoin. The cryptocurrency continues to face volatility but has decoupled from risk assets this week and has outperformed Gold.
  4. Pegasystems Inc. (NASDAQ:PEGA) shares upped 32.85% after reporting better-than-expected first-quarter financial results. Several analysts raised the price forecast for the stock.
  5. Impinj, Inc. (NASDAQ:PI) shares increased 31.58% after the company reported better-than-expected financial results and issued second-quarter guidance above estimates. Several analysts revised the price forecast for the stock.
  6. Lufax Holding Ltd (NYSE:LU) stock grew 30.72%, probably amid overall market strength due to March’s strong durable goods orders economic data and President Trump’s announcement that he met with China earlier today.
  7. Tempus AI Inc (NASDAQ:TEM) shares rocketed 30.09% after the company announced a multi-year collaboration with AstraZeneca PLC (NASDAQ:AZN) and Pathos AI.
  8. Kymera Therapeutics (NASDAQ:KYMR) stock was up 28.00%. The company initiated dosing in the BroADen phase 1B clinical trial evaluating KT-621, a potent degrader of STAT6, in patients with moderate to severe atopic dermatitis.

Photo by Piotr Swat via Shutterstock

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit:  https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.